PlainRecalls
FDA Drug Low Class III Terminated

Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1

Reported: April 19, 2023 Initiated: March 27, 2023 #D-0531-2023

Product Description

Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1

Reason for Recall

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.

Details

Recalling Firm
Pine Pharmaceuticals, LLC
Units Affected
932 syringes
Distribution
Nationwide in the USA
Location
Tonawanda, NY

Frequently Asked Questions

What product was recalled? ▼
Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1. Recalled by Pine Pharmaceuticals, LLC. Units affected: 932 syringes.
Why was this product recalled? ▼
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
Which agency issued this recall? ▼
This recall was issued by the FDA Drug on April 19, 2023. Severity: Low. Recall number: D-0531-2023.

Related Recalls

FDA Drug Moderate

Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: U…

Unichem Pharmaceuticals USA Inc. · 2026-02-11
FDA Drug Critical

Green Lumber Natural Fuel For Men capsule, packaged in 2, 4, 10, and 30-count blister packs. GreenLumber.com, 2618 San…

Green Lumber Holdings, LLC · 2026-02-11
FDA Drug Moderate

Trazodone Hydrochloride, USP, 50 mg, 100-Count Bottle, Rx only, Manufactured by: Granules India Limited, Hyderabad, 500…

Granules Pharmaceuticals Inc. · 2026-02-11
FDA Drug Critical

Diclofenac Sodium, Topical Gel, 3%, 100 g, Rx only, Mfd. by: Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1…

SUN PHARMACEUTICAL INDUSTRIES INC · 2026-02-11
FDA Drug Critical

Rheumacare capsules, 30 count bottle, Mfg in India by: Virgo UAP Pharma Pvt. Ltd., Ahmedabad, India UPC 8 904218 700313

HANDELNINE GLOBAL LLC · 2026-02-11

Explore Related Data

Vehicle Safety → Drug Information →